Literature DB >> 10891109

Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2.

M Otyepka1, V Krystof, L Havlícek, V Siglerová, M Strnad, J Koca.   

Abstract

The cell division cycle is controlled by cyclin-dependent kinases (cdk), which consist of a catalytic subunit (cdk1-cdk8) and a regulatory subunit (cyclin A-H). Purine-like inhibitors of cyclin-dependent kinases have recently been found to be of potential use as anticancer drugs. Rigid and flexible docking techniques were used for analysis of binding mode and design of new inhibitors. X-ray structures of three (ATP, olomoucine, roscovitine) cdk2 complexes were available at the beginning of the study and were used to optimize the docking parameters. The new potential inhibitors were then docked into the cdk2 enzyme, and the enzyme/inhibitor interaction energies were calculated and tested against the assayed activities of cdk1 (37 compounds) and cdk2 (9 compounds). A significant rank correlation between the activity and the rigid docking interaction energy has been found. This implies that (i) the rigid docking can be used as a tool for qualitative prediction of activity and (ii) values obtained by the rigid docking technique into the cdk2 active site can also be used for the prediction of cdk1 activity. While the resulting geometries obtained by the rigid docking are in good agreement with the X-ray data, the flexible docking did not always produce the same inhibitor conformation as that found in the crystal.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10891109     DOI: 10.1021/jm990506w

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  A validation study on the practical use of automated de novo design.

Authors:  Martin Stahl; Nikolay P Todorov; Tim James; Harald Mauser; Hans-Joachim Boehm; Philip M Dean
Journal:  J Comput Aided Mol Des       Date:  2002-07       Impact factor: 3.686

2.  Diverse effects of the cyclin-dependent kinase inhibitor bohemine: Concentration- and time-dependent suppression or stimulation of hybridoma culture.

Authors:  F Franek; M Strnad; L Havlícek; V Siglerová; I Fismolová; T Eckschlager
Journal:  Cytotechnology       Date:  2001-07       Impact factor: 2.058

3.  Transferable scoring function based on semiempirical quantum mechanical PM6-DH2 method: CDK2 with 15 structurally diverse inhibitors.

Authors:  Petr Dobeš; Jindřich Fanfrlík; Jan Rezáč; Michal Otyepka; Pavel Hobza
Journal:  J Comput Aided Mol Des       Date:  2011-02-01       Impact factor: 3.686

4.  Synthesis and biological evaluation of a selective N- and p/q-type calcium channel agonist.

Authors:  Mary Liang; Tyler B Tarr; Karla Bravo-Altamirano; Guillermo Valdomir; Gabriel Rensch; Lauren Swanson; Nicholas R DeStefino; Cara M Mazzarisi; Rachel A Olszewski; Gabriela Mustata Wilson; Stephen D Meriney; Peter Wipf
Journal:  ACS Med Chem Lett       Date:  2012-10-01       Impact factor: 4.345

5.  The mechanism of inhibition of the cyclin-dependent kinase-2 as revealed by the molecular dynamics study on the complex CDK2 with the peptide substrate HHASPRK.

Authors:  Iveta Bártová; Michal Otyepka; Zdenek Kríz; Jaroslav Koca
Journal:  Protein Sci       Date:  2005-01-04       Impact factor: 6.725

6.  Exploring the Activity of Fungal Phenalenone Derivatives as Potential CK2 Inhibitors Using Computational Methods.

Authors:  Sabrin R M Ibrahim; Alaa A Bagalagel; Reem M Diri; Ahmad O Noor; Hussain T Bakhsh; Yosra A Muhammad; Gamal A Mohamed; Abdelsattar M Omar
Journal:  J Fungi (Basel)       Date:  2022-04-24

7.  Several human cyclin-dependent kinase inhibitors, structurally related to roscovitine, are new anti-malarial agents.

Authors:  Sandrine Houzé; Nha-Thu Hoang; Olivier Lozach; Jacques Le Bras; Laurent Meijer; Hervé Galons; Luc Demange
Journal:  Molecules       Date:  2014-09-23       Impact factor: 4.411

8.  Adamantane-Substituted Purines and Their β-Cyclodextrin Complexes: Synthesis and Biological Activity.

Authors:  Michal Rouchal; Jana Rudolfová; Vladimír Kryštof; Veronika Vojáčková; Richard Čmelík; Robert Vícha
Journal:  Int J Mol Sci       Date:  2021-11-24       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.